COL7A1 and recessive dystrophic epidermolysis bullosa: Our research group conducted another phase 1/2 clinical trial investigating the effects of IV gentamicin in three RDEB patients with nonsense mutations in COL7A1 and reduced baseline expression of C7 at the DEJ [40].